menu
    • menu
    [{"orgOrder":0,"company":"Lysogene","sponsor":"Weizmann Institute Of Science","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Lysogene","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Lysogene \/ Weizmann Institute Of Science","highestDevelopmentStatusID":"1","companyTruncated":"Lysogene \/ Weizmann Institute Of Science"},{"orgOrder":0,"company":"Oncodesign","sponsor":"Servier","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"LRRK2","graph1":"Neurology","graph2":"Undisclosed","graph3":"Oncodesign","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Oncodesign \/ Servier","highestDevelopmentStatusID":"1","companyTruncated":"Oncodesign \/ Servier"},{"orgOrder":0,"company":"Crossject","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Steroid","year":"2025","type":"Collaboration","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Crossject","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Crossject \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Crossject \/ Eton Pharmaceuticals"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Crossject

                            France arrow
                            IFT FIRST
                            Not Confirmed

                            Crossject

                            France arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydrocortisone

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : Eton Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            CROSSJECT Updates on ZENEO Partnership with Eton for Adrenal Program

                            Details : ETON in-licensed commercialization rights to ZENEO® Hydrocortisone, a unique, and proprietary ready-to-use liquid formulation of hydrocortisone, for the US and Canadian markets.

                            Product Name : Zeneo

                            Product Type : Steroid

                            Upfront Cash : Undisclosed

                            March 25, 2025

                            Lead Product(s) : Hydrocortisone

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : Eton Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Oncodesign

                            France arrow
                            IFT FIRST
                            Not Confirmed

                            Oncodesign

                            France arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : Servier

                            Deal Size : $363.3 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Oncodesign and Servier Reach a Key First Milestone

                            Details : The partnership drew on the complementary expertise of Servier and Oncodesign in the fields of neurodegenerative diseases and macrocyclic kinase inhibitors.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $3.3 million

                            February 17, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : Servier

                            Deal Size : $363.3 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Lysogene

                            France arrow
                            IFT FIRST
                            Not Confirmed

                            Lysogene

                            France arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : Weizmann Institute Of Science

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Lysogene Enters Research Pact with Weizmann Institute of Science to Develop New AAV Gene Therapy

                            Details : The agreement involves collaboration, with the aim of developing a novel AAV gene therapy approach for neuronopathic Gaucher disease, Parkinson disease, and other diseases associated with mutations of the GBA1 gene.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            February 07, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : Weizmann Institute Of Science

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth